Definium Therapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Definium announced positive topline results from the Phase 3 Voyage study of DT120 ODT (lysergide 100 µg) in generalized anxiety disorder (n=214, 1:1 randomization vs. placebo). Primary endpoint: HAM-A score improved 5.4 points more than placebo at Week 12 (p<0.0001, Cohen's d=0.81). All key secondary endpoints also met. Safety profile consistent with prior studies; no new safety signals, no suicidality signal. This is Definium's second positive Phase 3 readout (first was Emerge in MDD in June). Panorama Phase 3 results in GAD expected September 2026.
Why this rating
Second major late-stage clinical success validates pipeline; strong effect size (d=0.81) and consistent results across indications materially de-risks regulatory path and commercial potential for ~$488M market-cap company; NDA pathway clearer
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.